# Clearside Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clearside-biomedical

- Industry: Biotechnology
- Headquarters: Alpharetta, US
- Website: www.clearsidebio.com
- Total disclosed funding: $51M
- Latest round: Series C (Dec 3, 2015)
- Investors on record: 11

## About

Clearside Biomedical, Inc. is a US-based biotechnology company that specializes in innovative drug delivery systems to treat eye diseases, focusing on precise administration methods for retinal conditions.Founded in 2012 and headquartered in Alpharetta, US, Clearside Biomedical, Inc. develops advanced drug delivery technologies for ocular treatments. The company underwent a successful IPO in June 2016, raising USD 50.4 mn, and has since engaged in multiple funding rounds. Mark Prausnitz is the founder, and George Lasezkay serves as the CEO.Clearside Biomedical is known for its proprietary suprachoroidal delivery system and its flagship product, XIPERE® (triamcinolone acetonide injectable suspension). This innovative FDA-approved treatment delivers medication directly to the suprachoroidal space, targeting conditions such as macular edema associated with uveitis. The SCS Microinjector®, a key device developed by the company, has been used in over 10,000 clinical procedures, enhancing drug delivery for various back-of-the-eye diseases including wet age-related macular degeneration and geographic atrophy, primarily in the US market with potential international expansion.For the most recent fiscal year 2024, Clearside Biomedical reported a revenue of USD 8.23 mn and an EBITDA of USD -24.84 mn, reflecting ongoing investments in their product offerings and operational strategies.Clearside Biomedical plans to leverage its recent funding to enhance ongoing research and development, focusing on launching new treatments in the retinal disease sector. The company aims to expand its market presence internationally while further developing its pipeline of ocular therapies. The latest funding round in January 2021 raised USD 12 mn, which will support these initiatives as Clearside seeks to introduce additional products to meet unmet medical needs in the ocular therapeutic space.

## Funding rounds

- Series C, Dec 3, 2015, $20M — AJU IB Investment, Rock Springs Capital, Cormorant Asset Management, Perceptive Advisors
- Series B, Sep 2, 2014, $16M — Hatteras Venture Partners, GRA Venture Fund, Mountain Group Partners, Santen Pharmaceutical Co., Ltd., RMI Partners
- Series A, Jan 31, 2013, $7.9M — Hatteras Venture Partners, GRA Venture Fund, Mountain Group Partners, UNC Kene-Flagler Business School, Santen Pharmaceutical Co., Ltd.
- Seed, Jan 5, 2012, $4M — Hatteras Venture Partners
- Series A, Jan 3, 2012, $3.2M — UNC Kenan-Flagler Private Equity Fund, GRA Venture Fund

## Investors

- UNC Kenan-Flagler Private Equity Fund (https://capitalatlas.ai/funds/unc-kenan-flagler-private-equity-fund) — Series A
- GRA Venture Fund (https://capitalatlas.ai/funds/gra-venture-fund) — Series A, Series B
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Seed, Series A, Series B
- Mountain Group Partners (https://capitalatlas.ai/funds/mountain-group-partners) — Series A, Series B
- UNC Kene-Flagler Business School — Series A
- Santen Pharmaceutical Co., Ltd. — Series A, Series B
- RMI Partners (https://capitalatlas.ai/funds/rmi-partners) — Series B
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series C
- Rock Springs Capital — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C